财务数据方面，丰倍生物2022-2024年分别实现营业收入17.09亿元、17.28亿元、19.48亿元，同比增长 率依次为31.89%、1.12%、12.75%；实现归母净利润1.33亿元、1.30亿元、1.24亿元，同比增长率依次为 30.85%、-2.73%、-4.54%。 据招股书介绍，丰倍生物的废弃油脂资源综合利用业务主要产品为生物基材料和生物燃料，其中生物基 材料主要为农药助剂、化肥助剂等生物柴油配方产品和工业级混合油；生物燃料主要为生物柴油；油脂 化学品业务主要产品为DD油、脂肪酸等。 截至2025年6月30日，丰倍生物及子公司已获得135项专利，其中国内发明专利33项，国际发明专利3 项。同时，公司被评为国家级专精特新"小巨人"企业、苏州市独角兽培育企业、苏州市企业技术中心 等，并挂牌成立了江苏省油脂加工副产品综合利用工程技术研究中心、苏州市油脂改性及综合利用工程 技术研究中心等。 客户资源方面，在生物燃料方面，丰倍生物客户覆盖TRAFIGURA、GLENCORE等全球知名大宗商品 交易商，以及BIOSYNTECHANDELSGMBH、CARGILLNV、SHELL、 REGINTERNATI ...

10月27日，可申购沪市主板的丰倍生物（603334.SH），公司成立于2014年，主营业务以废弃油脂资源 综合利用业务为主，油脂化学品业务为辅。 | 打新早知道 | | | 南财快讯 | | --- | --- | --- | --- | | 今日申购 | | | | | 603334.SH 丰倍生物 | | | | | 发行价(元/股) 机构报价(元/股) | | 市值(亿元) | 所属行业 | | 24.49 24.97 | | 26.35 | 非金属废料和碎屑 | | | | | 加工处理业 | | 发行市盈率 行业市盈率 | | 可比公司 | 可比公司动态市盈率 | | 30.47 64.73 | | 卓越新能 | 32.63 | | 嘉澳环保 | | | 号损 | | 隆海生物 | | | 亏损 | | 业绩情况 | | | | | 25.0 | | | 120% | | 20.0 | | | 100% | | | | | 80% | | 15.0 | | | 60% | | 10.0 | | | 40% | | | | | 20% | | 5.0 | | | 0% | | 0.0 2021年 2 ...

截至2024年末，公司现有生物柴油产能10.5万吨，产能规模位居我国生物柴油行业第六。丰倍生物表示，对比同行业可比 公司卓越新能、嘉澳环保（603822）和隆海生物，2024年公司扣除非经常性损益后归母净利润小于卓越新能，大于嘉澳环 保和隆海生物。 | 序号 | 公司名称 | 产能(万吨/年) | 产能占比率! | | --- | --- | --- | --- | | 1 | 卓越新能 | 50 | 14.20% | | 2 | 嘉澳环保 | 30 | 8.52% | | 3 | 河北金谷再生资源开发有限公司 | 30 | 8.52% | | 4 | 唐山金利海生物柴油股份有限公司 | 16 | 4.55% | | 5 | 上海中器环保科技有限公司 | 11 | 3.13% | | 6 | 发行人 | 10.5 | 2.98% | | 7 | 湖北天基生物能源股份有限公司 | 10 | 2.84% | | 8 | 湖北碧美新能源科技有限公司 | 10 | 2.84% | | 9 | 隆海生物 | 6 | 1.70% | | 10 | 山东丰汇新能源有限公司 | 6 | 1.70% | | | 合计 | 17 ...

中诚咨询也是周二申购。公司致力于为客户提供工程造价、招标代理、工程监理及管理、BIM服务、工 程设计等专业技术服务及全过程咨询服务。公司立足江苏，辐射周边省市，在南京、南通、徐州等地设 有分公司，并在安徽、江西、河北雄安等地开展业务。 公司预计2025年度实现营业收入38360.83万元，同比下降1201.94万元，降幅为3.04%；预计2025年度净 利润为10102.48万元，同比下降436.37万元，降幅为4.14%。业绩下降主要原因是受国际环境和宏观经 济复杂多变、房地产市场等因素影响。 丰倍生物2022年至2024年的营业收入分别为17.09亿元、17.28亿元和19.48亿元，呈现稳步增长态势。 同 期扣非净利润分别为1.36亿元、1.23亿元和1.15亿元，出现增收不增利的现象。盈利下滑的主要原因包 括欧盟反倾销政策的影响以及公司为适应市场变化而进行的产品结构调整。丰倍生物本次IPO拟募资7.5 亿元，全部用于新建年产30万吨油酸甲酯、1万吨工业级混合油、5万吨农用微生物菌剂、1万吨复合微 生物肥料及副产品生物柴油5万吨、甘油0.82万吨项目。 周二（28日）可申购的德力佳深耕精密齿轮传动领域， ...

智通财经APP讯，丰倍生物(603334.SH)发布首次公开发行股票并在主板上市招股意向书，本次拟公开 发行股票3,590.00万股，发行股份占发行后公司股份总数的比例为25.02%，全部为公开发行新股，本次 发行前股东所持发行人股份在本次发行时不向投资者公开发售。本次公开发行后总股本为14,350.00万 股。本次初始战略配售发行数量为718.00万股，占本次发行数量的20.00%。此次发行上市初步询价日期 2025年10月22日，申购日期为2025年10月27日。 公司是一家废弃资源综合利用领域的高新技术企业，主要以废弃油脂生产资源化产品。基于长期的研发 投入和产业实践，公司在废弃油脂资源综合利用的深度及广度上不断拓展，形成了"废弃油脂—生物燃 料(生物柴油)—生物基材料"的废弃资源再生产业链。此外，公司还依托自身油脂综合利用核心技术和 渠道优势为客户提供油脂化学品。 公司主营业务以废弃油脂资源综合利用业务为主，油脂化学品业务为辅。废弃油脂资源综合利用业务主 要产品为生物基材料和生物燃料，其中生物基材料主要为农药助剂、化肥助剂等生物柴油配方产品和工 业级混合油;生物燃料主要为生物柴油;油脂化学品业务主要产 ...

报告期各期，公司营业收入分别为170,869.32万元、172,778.32万元、194,801.63万元和147,812.92万元， 扣除非经常性损益后归母净利润分别为13,591.98万元、12,304.05万元、11,531.91万元和8,470.27万元。 报告期内，公司的收入规模整体呈现逐年增长的趋势并已形成一定规模，且主营业务收入占营业收入比 重持续保持在99%以上，主营业务突出、占比稳定。 公司是一家废弃资源综合利用领域的高新技术企业，主要以废弃油脂生产资源化产品。基于长期的研发 投入和产业实践，公司在废弃油脂资源综合利用的深度及广度上不断拓展，形成了"废弃油脂—生物燃 料(生物柴油)—生物基材料"的废弃资源再生产业链。此外，公司还依托自身油脂综合利用核心技术和 渠道优势为客户提供油脂化学品。 公司主营业务以废弃油脂资源综合利用业务为主，油脂化学品业务为辅。废弃油脂资源综合利用业务主 要产品为生物基材料和生物燃料，其中生物基材料主要为农药助剂、化肥助剂等生物柴油配方产品和工 业级混合油;生物燃料主要为生物柴油;油脂化学品业务主要产品为DD油、脂肪酸等。 丰倍生物(603334.SH)发布首次公开 ...

Company Overview - Suzhou Fengbei Biotechnology Co., Ltd. (Fengbei Bio) is preparing to list on the Shanghai Stock Exchange, aiming to raise 750 million yuan [2] - The company specializes in the comprehensive utilization of waste resources, primarily producing bio-based materials and biofuels from waste oils [4] Financial Performance - Fengbei Bio reported revenues of 1.71 billion yuan in 2022, 1.73 billion yuan in 2023, and projected 1.948 billion yuan in 2024, with net profits of 133 million yuan, 130 million yuan, and 124 million yuan respectively [4] - In the first half of 2025, the company achieved revenues of 1.478 billion yuan, a 49.62% increase from 988 million yuan in the same period of the previous year [7] - For the first nine months of 2025, Fengbei Bio expects revenues between 2.1 billion and 2.3 billion yuan, representing a growth of 51.40% to 65.82% compared to 1.387 billion yuan in the same period of 2024 [8] Shareholding Structure - Pingyuan controls 85.4% of Fengbei Bio, holding 59.78% directly and additional shares through subsidiaries [9] - Post-IPO, Pingyuan's shareholding will decrease to 44.82%, while other shareholders will hold smaller percentages [10] Project Financing - The current financing round will fund the construction of several projects, including an annual production capacity of 300,000 tons of oleic acid methyl ester and 50,000 tons of bio-diesel [3]

Group 1 - The China Securities Regulatory Commission approved Suzhou Fengbei Biotechnology Co., Ltd.'s initial public offering registration, with plans to raise 1 billion yuan [1] - Fengbei Biotechnology aims to list on the Shanghai Stock Exchange, with Guotai Junan Securities as its sponsor [1] Group 2 - Fengbei Biotechnology is a high-tech enterprise in the field of waste resource utilization, primarily producing resource-based products from waste oils [4] - The company has developed a waste resource recycling industry chain, focusing on "waste oils - biofuels (biodiesel) - bio-based materials" [4] - As of the end of 2024, the company's biodiesel production capacity is 105,000 tons, ranking sixth in China's biodiesel industry [4] - According to USDA statistics, China's biodiesel production is projected to be approximately 1.71 million tons in 2024, with Fengbei's biodiesel production at 80,100 tons, giving it a market share of about 4.68% based on production volume [4]

Core Viewpoint - Fengbei Biotechnology Co., Ltd. has successfully submitted its IPO registration on the Shanghai Stock Exchange, focusing on the comprehensive utilization of waste resources, particularly converting waste oils into biodiesel and bio-based materials, but faces challenges including performance decline due to EU anti-dumping policies and weak R&D investment [1][10][24]. Group 1: Company Overview - Fengbei Biotechnology is a high-tech enterprise in the waste resource utilization sector, primarily producing biodiesel and bio-based materials from waste oils, forming a recycling industry chain [2][5]. - The company was established in July 2014 and transitioned to a joint-stock company in January 2022, with its founder, Ping Yuan, holding 85.40% of the shares [4][5]. Group 2: Financial Performance - For the years 2022 to 2024, Fengbei's operating revenues were 1.709 billion, 1.728 billion, and 1.948 billion yuan, with year-on-year growth rates of 31.89%, 1.12%, and 12.75% respectively [10][11]. - The net profit attributable to the parent company for the same period was 133 million, 130 million, and 124 million yuan, showing a decline of 2.73% and 4.54% in the last two years [10][11]. Group 3: Market Challenges - The company has faced significant challenges due to the EU's anti-dumping investigations, which have led to a sharp decline in sales in the EU market, affecting overall profitability [15][18]. - Sales to the EU dropped from 3.30 billion yuan in 2021 to 505 million yuan in the first half of 2024, indicating a substantial market shift [15][18]. Group 4: R&D and Competitive Position - Fengbei's R&D expenses as a percentage of operating income were 3.00%, 3.39%, and 2.75% from 2022 to 2024, which is below the industry average [21][22]. - The company claims its competitive advantage lies in basic research, material development, and application development, but it risks falling behind competitors if R&D investment does not increase [24]. Group 5: Financial Health - As of the end of 2024, Fengbei's cash reserves were 167 million yuan, while short-term borrowings amounted to 173 million yuan, indicating potential liquidity issues [24].

Core Viewpoint - Fengbei Bio is a high-tech enterprise in the field of waste resource utilization, focusing on converting waste oils into biodiesel and bio-based materials, but faces challenges such as declining performance due to EU anti-dumping policies and insufficient R&D investment [2][14][20]. Company Overview - Fengbei Bio was established in July 2014 and transitioned to a joint-stock company in January 2022, with a registered capital of 5 million yuan [4]. - The founder, Ping Yuan, holds 85.40% of the shares, maintaining absolute control over the company [4][5]. - The company has acquired stakes in several related companies to enhance its operational scale and market competitiveness [4][6]. Financial Performance - Revenue for 2022, 2023, and projected 2024 is 1.709 billion yuan, 1.728 billion yuan, and 1.948 billion yuan, respectively, showing a growth of 31.89%, 1.12%, and 12.75% [9][10]. - Net profit for the same years is 133.34 million yuan, 129.71 million yuan, and 123.82 million yuan, indicating a decline of 2.73% and 4.54% in 2023 and 2024 [9][10]. - The company has distributed significant cash dividends of 15 million yuan and 16.14 million yuan in 2022 and 2023, respectively, totaling 31.14 million yuan [7]. Market Challenges - The company faces a significant decline in sales to the EU due to anti-dumping investigations, with sales figures dropping from 3.30 billion yuan in 2021 to 505.12 million yuan in the first half of 2024 [16][18]. - The EU accounts for 34.65% of global biodiesel consumption, making it a critical market for Fengbei Bio [12]. R&D and Competitive Position - R&D expenses as a percentage of revenue have decreased from 3.39% in 2023 to 2.75% in 2024, which is below the industry average [20][21]. - The company’s biodiesel production capacity is 105,000 tons, significantly lower than competitors like Zhuoyue New Energy and Jiaao Environmental Protection [22]. Future Outlook - The company is shifting its sales focus to emerging markets outside the EU, such as Switzerland and Singapore, in response to changing policies [15]. - The company’s financial health is concerning, with cash reserves of 167 million yuan against short-term borrowings of 173 million yuan, indicating potential liquidity issues [24][25].